January 21, 2015
HelomicsTM to present at the Personalized Medicine World Conference

January 12, 2015
HelomicsTM supports the Work of the UK's Personalised Healthcare Alliance

January 6, 2015
HelomicsTM to Present at Biotech Showcase 2015 During the JP Morgan Healthcare Conference


November 18, 2014
HelomicsTM to Be Recognized at the 2014 Pittsburgh Smart 50 Awards

November 12, 2014
Precision Therapeutics Transforms into Helomics™ Corporation

July 22, 2014
Manuscript Demonstrating ChemoFx is a Predictive Marker in Ovarian Cancer Published by the British Journal of Cancer

July 17, 2014
Precision Therapeutics Supports the Annual National Ovarian Cancer Coalition (NOCC) Run/Walk to Break the Silence

June 26, 2014
Two Pivotal Manuscripts on ChemoFx Accepted for Publication

June 7, 2014
TechVibe Radio Interview with Sean McDonald:
Part 1
Part 2

February 24, 2014
Data Demonstrating the Ability of ChemoFx® to Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior to Treatment Published by the American Journal of Obstetrics and Gynecology

February 11, 2014
Patient Story by Katya Lezin: My cancer cells are growing nicely – in a Petri dish

January 30, 2014
Precision Therapeutics, Partners Validate Almac's ColDx Colorectal Cancer Test ahead of US Launch

January 28, 2014
Data Presented Supporting Precision Therapeutics’ GeneFx® Colon Signature as a Significant Predictor of Risk of Recurrence in Stage II Colon Cancer


December 16, 2013
Precision Therapeutics Uses Automated Method to Extract RNA for Use in the GeneFx(R) Colon Signature

November 5, 2013
Precision Therapeutics Presents Clinical Data Showing the ChemoFx® Drug Response Test Has Predictive Value in Recurrent Epithelial Ovarian Cancer

September 9, 2013
Precision Therapeutics' Analytical Study Evaluating the Ability of GeneFxTM Colon to Identify Risk of Recurrence for Stage II Colon Cancer Patients Accepted for Publication

September 5, 2013
Personalized Treatment For Ovarian Cancer Has Positive Results

September 4, 2013
Precision Therapeutics Announces New Gynecologic Cancer Registry in Collaboration with SGO

August 26, 2013
Test analyzes chemotherapy effectiveness for ovarian cancer

August 22, 2013
Precision Therapeutics Supports Research Institute

August 22, 2013
Chemoresponse Assay Demonstrates Utility in Recurrent Ovarian Cancer

August 21, 2013
Assay Accurately Predicts Tx Response in Ovarian Cancer

August 21, 2013
With Prospective Data, Precision Therapeutics Hoping to Ramp up ChemoFx Adoption, Reimbursement

August 20, 2013
Ovarian Cancer Chemoresponse Assay Demonstrates Utility

August 19, 2013
Precision Therapeutics Announces Unparalleled Results That Show Recurrent Ovarian Cancer Patients Live 65% Longer in Breakthrough Prospective Clinical Trial

August 19, 2013
Precision Therapeutics Study Shows Promise

August 13, 2013
Precision Therapeutics Provides Ongoing Support to the National Ovarian Cancer Coalition (NOCC) Pittsburgh Chapter

July 11, 2013
Value of Precision's Test Shown

July 11, 2013
Research by Allegheny Health Network Physician Finds Test Developed Locally Accurately Predicts Women’s Response to Platinum-Based Ovarian Cancer Treatment

July 8, 2013
ChemoFx® Chemoresponse Assay Identifies Platinum-Resistance in Primary Ovarian Cancer Patients

June 19, 2013
Pretests of Cervical Tumors Could Inform Treatment

June 19, 2013
Precision Therapeutics to Present Clinical Data Showing Significant Association between ChemoFx® Results and Improved Outcomes in Recurrent Ovarian Cancer at the 2013 European Cancer Congress

May 9, 2013
Precision Therapeutics Presents Clinical Data Demonstrating Prediction for Platinum Resistance to First-Line Chemotherapy in Primary Ovarian Cancer at WAGO

May 6, 2013
Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to Be Presented by Precision Therapeutics at WAGO Annual Meeting

April 30, 2013
An Independent Clinical Study Shows Association between ChemoFx® Results and Recurrence Free Survival in Cervical Cancer

April 25, 2013
Research: Chemoresponse assay helps boost ovarian cancer survival

March 27, 2013
Med BioGene Announces New Marketing Name for Lung Cancer Test

March 13, 2013
Chemoresponse assays may markedly boost ovarian cancer survival

March 11, 2013
Precision Therapeutics Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer using Personalized Chemotherapy Diagnostic ChemoFx®

January 23, 2013
Precision Therapeutics and Med BioGene Announce Successful Completion of LungExpress DxTM Clinical Studies; Precision Therapeutics Prepares for Commercial Launch


December 4, 2012
ChemoFx® Used to Develop Multi-Gene Predictors to Chemotherapy in Breast Cancer

November 14, 2012
ChemoFx Results Show Differences in Chemoresponse between Optimally and Sub-Optimally Debulked Primary Ovarian Cancers

November 12, 2012
New Study Supports Potential Utility of ChemoFx in Primary Ovarian Cancer

November 1, 2012
New Study Shows Association between ChemoFx Results and Recurrence Free Survival

October 2, 2012
Rosetta, Precision Launch MiRview Mets2 Assay In U.S. Oncology Market

September 6, 2012
Precision Therapeutics’ ChemoFx® Test Useful in Determining Treatment for Resistant and Recurrent Gynecologic Cancer Patients

August 21, 2012
Precision Therapeutics Post Issue 11

July 24, 2012
Rosetta Genomics and Precision Therapeutics Enter into Co-Marketing Agreement for miRview® mets(2) Assay

July 18, 2012
Four Abstracts on ChemoFx® to Be Presented at IGCS Annual Meeting

June 6, 2012
Precision Therapeutics Presents GeneFx Colon Signature at the American Society of Colon and Rectal Surgery Symposium (ASCRS), the World's Largest Colorectal Conference

June 4, 2012
ChemoFx Provides Tumor-Specific Information That May Assist in Personalized Chemotherapy Selection

May 31, 2012
Precision Therapeutics Releases Data Determining the Clinical Use of ChemoFx in Helping to Select Treatment for Patients with Cervical Cancer

May 21, 2012
Three Abstracts on the ChemoFx Drug Response Marker Accepted by ASCO

May 16, 2012
Precision Therapeutics Supports The 12th Annual Women's Health & Fitness Expo 2012 in Honor of National Women's Health Week

March 2, 2012
Startup Weekend Coming to Pittsburgh

January 24, 2012
Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care

January 3, 2011
Sean McDonald handles growth and change at Precision Therapeutics, Inc.



November 14, 2011
Precision Therapeutics Post

October 1, 2011
Sean McDonald Featured in Smart Business

September 21, 2011
Precision's Kord Kozma is one of Thirteen Human Resources Professionals Honored at Pittsburgh Business Time's 2011 HR Leadership Awards

September 8, 2011
See Precision's Profile on the Inc. 500/5000

September 7, 2011
Precision Therapeutics Presents Multi-Gene Breast Cancer Studies at 2011 Breast Cancer Symposium

August 26, 2011
Precision Therapeutics Inc. Prepares to Bring New Products to Markets

August 23, 2011
Precision Therapeutics Named on Inc. 500|5000 2011 List and Recognized for Achievements in Personalized Medicine Industry

July 6, 2011
Precision Therapeutics' Largely Young Workforce is Helping Patients Fight Cancer with Individualized Drug Therapies in Directing Chemotherapy in Gynecologic Cancers

June 6, 2011
Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx in Directing Chemotherapy in Gynecologic Cancers

June 6, 2011
Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients

June 1, 2011
Precision Therapeutics Post

May 6, 2011
Video (may take time to download): Precision Investor Bain Capital Ventures

April 27, 2011
Sean McDonald Interviewed on Health Talk Radio

April 18, 2011
Med Biogene Announces Closing of Partnership With Precision Therapeutics to Commercialize LungExpress DX

April 13, 2011
Precision Therapeutics' ChemoFx Demonstrates Significant Role In Selection of Chemotherapy Doublets In Non Small Cell Lung Cancer

April 7, 2011
Precision Therapeutics Announces New Tumor Profiling Product to Augment Utility of ChemoFx® and Further Personalize Cancer Treatment

April 2, 2011
Interview by WTAE Radio: The American Entrepreneur: How Precision Therapeutics Survived the Recession: A Conversation with CEO Sean McDonald and Ron Morris

March 19, 2011
Video: Sean McDonald Interviewed by Our Region's Business

March 1, 2011
Precision Therapeutics and Med BioGene Partner to Commercialize LungExpress DxTM

January 19, 2011
Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx in Cancer Treatment Options

January 17, 2011
Precision Therapeutics Announces New Study on Multi-Gene Predictors at 2010 San Antonio Breast Cancer Symposium


December 2, 2010
Precision Therapeutics To Present Abstracts At 33rd Annual San Antonio Breast Cancer Symposium

October 15, 2010
Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year

September 22, 2010
Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award

September 7, 2010
Precision Therapeutics Continues Dedicated Support to the NOCC 'Walk to Break the Silence'

September 2, 2010
Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100

August 27, 2010
Precision Therapeutics Inc. Maintains Growth by Adopting Basic Business Concepts

August 26, 2010
Precision Makes List of Pittsburgh's Fastest Growing Companies

June 30, 2010
Precision Therapeutics Featured in Pop City News

June 30, 2010
Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts

June 16, 2010
Precision Therapeutics reels in $33M, hiring and opening a lab in the Chocolate Factory

June 11, 2010
Pittsburgh Business Times Article: Precision Therapeutics lands $33 million in venture capital

June 3, 2010
ChemoFx® Drug Response Marker Delivers Substantial Cost Savings

April 15, 2010
Precision Therapeutics to Present Abstracts at American Association for Cancer Research Meeting

March 2, 2010
Chemosensitivity/Resistance Assay Included As Part of the NCCN Principles of Chemotherapy

Feruary 3, 2010
Patients, Physicians Rely on ChemoFx® to Support Their Cancer Treatment Decisions

January 21, 2010
Precision Therapeutics CEO Presents at J.P. Morgan 28th Annual Healthcare Conference

January 21, 2010
Precision Therapeutics to Present at Jeffries 2010 Global Healthcare Services Conference


November 2009
Precision Quarterly Newsletter

October 2, 2009
Precision Therapeutics heading to Pittsburgh's Lawrenceville neighborhood

September 21, 2009
Precision Therapeutics President and CEO Sean McDonald Recipient of 2009 Pacesetter Award

September 10, 2009
Pittsburgh-based tech firm clarifies approval

September 2009
INC. Magazine names Precision Therapeutics one of the fastest growing private companies

June 2009
Precision Quarterly Newsletter

May 18, 2009
OCNA sends an open letter to the Payer community

May 2009
ChemoFx® offers hope to cancer patients

March 1, 2009
Precision's Quarterly Newsletter

Archived News